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A B S T R A C T
Background
Tuberculosis (TB) is an important cause of illness and death in HIV-positive children living in areas of high TB prevalence. We know
that isoniazid prophylaxis prevents TB in HIV-negative children following TB exposure, but there is uncertainty related to its role in
TB preventive treatment in HIV-positive children.
Objectives
To summarise the effects of TB preventive treatment versus placebo in HIV-positive children with no known TB contact on active TB,
death, and reported adverse events.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE/PubMed, Embase and two trial registers
up to February 2017.
Selection criteria
We included trials of HIV-positive children with and without known TB exposure, randomized to receive TB preventive treatment or
placebo.
Data collection and analysis
Two review authors independently used the study selection criteria, assessed risk of bias, and extracted data. We assessed effects using
risk, incidence rate and hazard ratios and assessed the certainty of evidence using GRADE.
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Main results
We included three trials, involving 991 participants, below the age of 13 years, from South Africa and Botswana. Children were
randomized to isoniazid prophylaxis or placebo, given daily or three times weekly. The median length of follow-up ranged from 5.7 to
34 months; some were on antiretroviral therapy (ART).
In HIV-positive children not on ART, isoniazid prophylaxis may reduce the risk of active TB (hazard ratio (HR) 0.31, 95% confidence
interval (CI) 0.11 to 0.87; 1 trial, 240 participants, low certainty evidence), and death (HR 0.46, 95% CI 0.22 to 0.95; 1 trial, 240
participants, low certainty evidence). One trial (182 participants) reported number of children with laboratory adverse events, which
was similar between the isoniazid prophylaxis and placebo groups. No clinical adverse events were reported.
In HIV-positive children on ART, we do not know if isoniazid prophylaxis reduces the risk of active TB (risk ratio (RR) 0.76, 95% CI
0.50 to 1.14; 3 trials, 737 participants, very low certainty evidence) or death (RR 1.45, 95% CI 0.78 to 2.72; 3 trials, 737 participants,
very low certainty evidence). Two trials (714 participants) reported number of clinical adverse events and three trials (795 participants)
reported number of laboratory adverse events; for both categories, the number of adverse events were similar between the isoniazid
prophylaxis and placebo groups.
Authors’ conclusions
Isoniazid prophylaxis given to all children diagnosed with HIV may reduce the risk of active TB and death in HIV-positive children
not on ART in studies from Africa. For children on ART, no clear benefit was detected. .
P L A I N L A N G U A G E S U M M A R Y
Isoniazid prophylaxis for preventing active tuberculosis and death in HIV-positive children
What was the aim of this review?
To summarise the effects of isoniazid prophylaxis on TB, death, and adverse effects in HIV-positive children.
Key messages
In areas of high tuberculosis endemicity, isoniazid prophylaxis prevents active TB and death in HIV-positive children who are not on
ART.
We conducted a review to assess the effect of TB medication on active TB or death and its safety in HIV-positive children.
What was studied in the review?
TB is a common cause of severe lung disease and death inHIV-positive children. Childhood TB is common in poor countries, especially
those with a coexisting burden of HIV/AIDS disease. HIV-positive children have a higher risk of developing TB than HIV-negative
children. Isoniazid prevents TB in HIV-positive adults and is currently used in children who are at high risk of developing TB disease
after exposure to someone with TB. However, there is limited information on the effect of isoniazid medication in reducing active TB
or death if given to HIV-positive children without known TB contact.
We searched for studies up to 17 February 2017, and found three studies published between 2007 and 2014 that addressed the effect
of isoniazid medication compared to no medication on active TB and death in 991 HIV-positive children, below the age of 13 years.
Most of the children were on antiretroviral therapy (ART) and the studies were conducted in South Africa and Botswana. The median
length of follow-up ranged from 5.7 to 34 months.
What are the main results of the review?
In HIV-positive children not taking ART, isoniazid medication reduced the number of children developing active TB by 69% (low
certainty evidence), and death by 54% (low certainty evidence).
One trial was conducted in HIV-positive children taking ART, and this did not detect any benefit or harm of isoniazid (very low certainty
evidence).
The number of children with adverse effects were similar in children receiving isoniazid medication as the control group in both children
on ART and not on ART.
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How up to date is the review?
The review authors searched for studies published up to February 2017.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Isoniazid prophylaxis compared to placebo for HIV-positive children not on antiretroviral therapy (ART)
Patient or population: HIV-posit ive children not taking ART
Settings: any sett ing
Intervention: isoniazid prophylaxis daily or three t imes weekly
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comment
Assumed risk Corresponding risk
Placebo Isoniazid prophylaxis
Active TB 10 per 100 3 per 100
(1 to 9)
HR 0.31
(95%CI 0.11 to 0.87)
240
(1 trial)
⊕⊕©©
low1,2,3,4,5
due to serious indirect-
ness and imprecision
Isoniazid prophylaxis
may reduce act ive TB
Death 17 per 100 8 per 100
(8 per 17)
HR 0.46
(95%CI 0.22 to 0.95)
240
(1 trial)
⊕⊕©©
low1,2,3,4,5
due to serious indirect-
ness and imprecision
Isoniazid prophylaxis
may reduce death
The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95%CI) is based on the assumed risk in the comparison group
and the relative effect of the intervent ion (and its 95% CI).
Abbreviations: CI: conf idence interval; RR: risk rat io; HR: hazard rat io.
GRADE Working Group grades of evidence
High certainty: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate certainty: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low certainty: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low certainty: we are very uncertain about the est imate.
4
Iso
n
ia
z
id
fo
r
p
re
v
e
n
tin
g
tu
b
e
rc
u
lo
sis
in
H
IV
-in
fe
c
te
d
c
h
ild
re
n
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
7
T
h
e
A
u
th
o
rs.
C
o
c
h
ra
n
e
D
a
ta
b
a
se
o
f
S
y
ste
m
a
tic
R
e
v
ie
w
s
p
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
o
n
b
e
h
a
lf
o
f
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
1No serious risk of bias: this trial was at low risk of select ion bias, and adequately blinded study part icipants and personnel.
However, the study was stopped early on the recommendation of the data safety monitoring board af ter only 277 of the
planned 432 were enrolled. Not downgraded.
2No serious inconsistency: a single trial.
3Downgraded by 1 for serious indirectness: this single trial is f rom a single sett ing in South Af rica. Broad generalizat ion of
this result to other sett ings is dif f icult given the variat ion in isoniazid resistance worldwide.
4Downgraded by 1 for serious imprecision: there were very few events in this trial and as such the f inding is f ragile. The
original paper reports the result using a hazard rat io and the result reached standard levels of stat ist ical signif icance.
5We reported the study authors’ data.
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B A C K G R O U N D
Description of the condition
Tuberculosis (TB) is an important cause of childhood morbid-
ity and death especially in HIV-positive children (Kochi 1991;
Donald 2002). Infection is caused by Mycobacterium tuberculosis
and most commonly results in acute and chronic respiratory dis-
ease (Foster 2003). In 1994, the incidence of childhood TB in-
creased in low- and middle-income countries (Nelson 2004). This
resurgence was partly attributed to the coexisting burden of HIV
disease (WHO 2012), which is most pronounced in sub-Saharan
Africa. At the end of 2012, an estimated 3.3million children under
15 years of age, were living with HIV (UNAIDS/WHO 2013),
and 260,000 new HIV infections in children in low- and middle-
income countries were reported the same year (UNAIDS/WHO
2013). The World Health Organization (WHO) estimates that,
of the 8.7 million incident cases of TB in 2011, approximately
500,000 occurred in children under 15 years of age (WHO2012).
However, the burden of childhood TB disease is not as well docu-
mented as in adults, partly because of the difficulty of confirming
the diagnosis.
Dual infection with TB has an important impact on HIV dis-
ease. TB accelerates the progression of HIV disease by increasing
viral replication (Whalen 1995; Goletti 1996). TB is a common
cause of acute pneumonia in African HIV-positive children (Zar
2001; Jeena 2002), andmay lead to chronic lung disease, including
bronchiectasis (Ikeogu 1997; Jeena 1998). TB is a common cause
of death in HIV-positive children (Ikeogu 1997; Chintu 2005).
Antimycobacterial drugs, such as rifampicin, have deleterious drug
interactionswith antiretroviral therapy (ART), complicating treat-
ment. Rifampicin, an inducer of cytochrome P450 CYP3A, de-
creases the concentration of both the protease inhibitors and non-
nucleoside reverse transcriptase inhibitors, leading to sub-thera-
peutic levels, and increasing the risk for inadequate viral suppres-
sion and consequent drug resistance (Ren 2008; Ren 2009). The
large pill burden of two multiple drug regimens increases the risk
of adverse events, such as liver toxicity and the likelihood of poorer
adherence (Burman 2005).
Conversely, HIV infection has an impact on TB disease. HIV-
positive children have a higher risk of developing primary TB than
HIV-negative children (Mukadi 1997; Hesseling 2009). The di-
agnosis of TB is more difficult in HIV-positive children, as other
infections or HIV disease may mimic TB. Furthermore, tuber-
culin skin testing is less sensitive due to immunosuppression, and
chest radiography is less specific (Berggren Palme 2002; Chintu
2005). The outcome of HIV-positive versus HIV-negative chil-
dren with TB co-infection is poorer, with six-fold increased death
in HIV-positive children not on ART (Berggren Palme 2002;
Hesseling 2005). The cure rate of TB in HIV-positive children
not on ART is significantly lower than in HIV-negative children
(Mukadi 1997; Berggren Palme 2002), with a higher rate of recur-
rence (Schaaf 2005). HIV-positive children may therefore require
a longer course of TB treatment (Perriens 1995; Schaaf 1998).
HIV-positive children, stable on ART, are less likely to develop
TB disease and have a better outcome than those not on ART
(Walters 2008; Edmonds 2009; Martinson 2009). However, the
initiation of ART in the setting of TB co-infection can lead to
a paradoxical worsening of TB from the ’immune reconstitution
syndrome’ (Narita 1998; Puthanakit 2006; Zampoli 2007; Smith
2009). Moreover, the risk of TB in HIV-positive children on ART
is still higher than that of HIV-negative children (Madhi 2011).
Description of the intervention
Isoniazid preventive treatment (IPT) is a secondary prevention
strategy, whereby isoniazid prevents progression of latent TB to
active TB in those at high-risk of developing active TB (Cohen
2006). The WHO currently recommends that HIV/AIDS pro-
grammes include IPT as part of their package of care for HIV-
positive people. Current guidelines recommend six months of IPT
for HIV-positive children aged one year and above, without TB
disease, even in the absence of a known TB contact; IPT for up
to 3 years of use is recommended in HIV-positive adolescents or
adults (WHO 2010; WHO 2011).
How the intervention might work
Preventing TB infection and disease in HIV-positive children is
potentially an important public health intervention. Isoniazid has
been used successfully as preventive treatment in HIV-negative
children following TB exposure (Smieja 1999), and in HIV-in-
fected adults with a positive tuberculin skin test (Akolo 2010),
where treatment reduced TB disease by 62%.This benefit was
found for all preventive drug regimens: isoniazid alone, isoniazid
with rifampicin, rifampicin with pyrazinamide and isoniazid, ri-
fampicin and pyrazinamide. No reduction in death was found.
Isoniazid offers a further 40% reduction in active TB amongHIV-
positive adults on ART (Rangaka 2014). Studies showed that IPT
reduces active TB at the community and population level (Grant
2005 ). However, the strategy may be compromised by low adher-
ence over the many months necessary to complete a single course
of IPT, a problem worsened in HIV-TB co-infected individuals
for whom IPT durations are prolonged. In contrast to adults, pre-
ventive treatment in children is aimed at preventing primary in-
fection rather than reactivation of disease (WHO 2011). In set-
tings of high TB prevalence, the rate of TB re-infection is high
(Verver 2005), and short-course prophylaxis is potentially inade-
quate. Longer-term prophylaxis or repeat courses may be neces-
sary. Preventive treatment can lead to adverse events, mostly liver
toxicity, although this is uncommon and rarely requires cessation
of antimycobacterial medication in HIV-positive children (Gray
2009a; Donald 2000; Gray 2009a; Le Roux 2013).The benefits
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of isoniazid outweigh the risk of liver damage for HIV-infected
people (Getahun 2010).
Why it is important to do this review
In high-TB prevalence areas, TB preventive treatment may be
effective in preventing infection and development of disease in
HIV-positive children. The efficacy of preventive treatment may,
however, be limited by adherence difficulties, adverse events, and
cost implications. The true efficacy of TB preventive treatment
in HIV-positive children must be clearly established and balanced
against the occurrence of these events. We decided to undertake
a Cochrane Review on the efficacy and safety of TB preventive
treatment in HIV-positive children with prophylaxis started in all
children diagnosed with HIV infection.
O B J E C T I V E S
To summarise the effects of TB preventive treatment versus
placebo in HIV-positive children with no known TB contact on
active TB, death, and reported adverse events.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomized controlled trials (RCTs) that evaluated
the efficacy of TB preventive treatment in participants randomly
allocated to preventive treatment for TB and placebo.
Types of participants
We included HIV-positive children, below 13 years, without TB
disease currently (irrespective of prior history of TB treatment,
infection or prophylaxis). We included children on antiretroviral
therapy (ART). For studies that included eligible and non-eligible
participants, we included only effect estimates of eligible partici-
pants.
Types of interventions
• Intervention group: any TB drug or drug combination.
• Comparison group: inactive placebo.
We did not impose any restrictions on study interventions, such
as dose, duration of treatment, timing of outcome measurement,
or co-interventions.
Types of outcome measures
Primary outcomes
• Active TB
We defined definite TB by a microbiological or histological iden-
tification of Mycobacterium tuberculosis. We based the diagnosis
of probable TB on a combination of typical clinical symptoms
and signs, tuberculin skin testing, chest radiography, a history of
close TB contact, and a documented response to antimycobacte-
rial treatment.
Secondary outcomes
• Death
• Grade 3 or higher clinical adverse events
◦ Peripheral neuropathy (defined as sensory alteration or
paraesthesia causing inability to perform usual social and
functional activities or disabling sensory alteration or
paraesthesia causing inability to perform age appropriate basic
self-care functions) (NIAID 2014)
◦ Other clinical adverse events
• Grade 3 or higher laboratory adverse events
◦ Haematological abnormalities (defined as neutrophil
count of 500/mm3 to 749/mm3 or < 500/mm3 ; platelet count of
25,000 to 49,999/mm3 or < 25,000/mm3 ; haemoglobin of 6.5
g/dL to 7.5 g/dL or < 6.5 g/dL) (NIAID 2014)
◦ Liver enzyme abnormalities (raised alanine
aminotransferase and aspartate aminotransferase of 5.1 to 10 or
> 10, the upper limit of normal) (NIAID 2014)
◦ Other laboratory adverse events
We graded adverse events according to the standardized paediatric
AIDS clinical trial grading system of severity of adverse events
(NIAID 2014).
Search methods for identification of studies
Electronic searches
We searched:
• MEDLINE/PubMed (1946 to 17 February 2017)
Appendix 1;
• Cochrane Central Register of Controlled Trials
(CENTRAL), in the Cochrane Library (17 February 2017)
Appendix 2; and
• Embase (1974 to 17 February 2017) Appendix 3.
We also searched for ongoing RCTs of chemoprophylaxis in HIV-
positive children in:
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• World Health Organization International Clinical Trials
Registry Platform (WHO ICTRP) (www.who.int/ictrp; to 17
February 2017); and
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov; to 17 February 2017).
Searching other resources
Wehandsearched reference lists of identified articles and review ar-
ticles. We screened abstracts and proceedings of the International
Union Against Tuberculosis and Lung Disease (IUATLD) World
Congress, the American Thoracic Society International Congress,
and the European Respiratory Society World Congress confer-
ences. We contacted investigators of identified trials and other
content experts to locate information on any further trials that
may not have been included in the electronic databases or pre-
sented at conferences, to find out whether these were completed,
ongoing, or published. We scrutinized non-Cochrane reviews for
any additional relevant studies or unpublished data.
Data collection and analysis
Selection of studies
MZ and TY scrutinized studies independently for eligibility. We
retrieved the full text of relevant articles and independently ex-
amined them for eligibility. We included studies if they met the
prespecified eligibility criteria. Authors assessing study eligibility
were not blinded to the names of the trial investigators, their in-
stitutions, journals of publication or results of study. Reasons for
excluding studies are summarized in Characteristics of excluded
studies. We record the selection process in sufficient detail to com-
plete a PRISMA flow diagram Liberati 2009.
Data extraction and management
MZand a research assistant (OA) extracted the data. The following
study characteristics and outcomes were independently extracted
in duplicate, under the following subheadings:
• Methods (study design, study duration, methodological
quality).
• Participants (inclusion and exclusion criteria, number of
patients randomized, setting).
• Interventions (allocated treatment and dosage regimen,
treatment duration)
• Outcomes (active TB, death, clinical and laboratory adverse
events).
• Study results (number of participants with event of interest
and the total number in that study arm for dichotomous
outcomes; number lost to follow-up, and how incomplete data
were addressed)
Review authors who authored an included study did not partici-
pate in data extraction and assessment of risk of bias of included
studies to maintain independence of the review. We summarized
data in the Characteristics of included studies tables.
Assessment of risk of bias in included studies
WeusedCochrane’s ’Risk of bias’ tool to assess the included studies
(Deeks 2008; Higgins 2011). MZ and OA independently assessed
the methodological quality of the included studies. We assessed
the following domains.
• The adequacy of generation of allocation sequence and
allocation concealment in preventing selection bias.
• The presence or absence of blinding of the participant and
personnel to reduce performance bias.
• The method of outcome assessment: whether the same
method of assessment was used in both groups and presence or
absence of blinding of outcome assessor in the prevention of
detection bias.
• Attrition bias by looking at the percentage of participants
included in final analyses and the description of those not
included. We also assessed whether or not an intention-to-treat
analysis was performed.
• We compared protocols of included studies with published
articles to assess for risk of selective reporting bias.
• Other bias.
We assigned the following judgements for risk of bias for each
domain: low risk, high risk, and unclear risk of bias. We resolved
disagreements on eligibility and methodological quality of trials
by discussion and by obtaining further information from trial au-
thors. We summarized data in a ’Risk of bias’ table and graph,
which shows our judgements on risk of bias in each domain, for
each study separately, and as a percentage across all included stud-
ies.
Measures of treatment effect
For binary outcomes, we calculated risk ratios (RRs) and associated
95% confidence intervals (CIs). We assessed the effect of the in-
tervention (isoniazid prophylaxis) compared to control (placebo)
on the time to event (death and developing TB) with the hazard
and incidence rate ratios (95% CI) presented in study reports.
Dealing with missing data
Two included trials used an intention-to-treat analysis to address
missing data from participant dropout and the attrition rate was
low in the third trial. We contacted the primary author of one
included study formissing summary statistics, however, the author
did not respond.
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Assessment of heterogeneity
We used the Chi2 test and I2 statistic to assess statistical hetero-
geneity (Deeks 2008). We considered statistical heterogeneity to
be substantial when the Chi2 test, which assesses if the observed
differences in results are due to chance alone, had a P value of <
0.10 and when the I2 statistic, describing the percentage of vari-
ability in effect estimates due to heterogeneity, was > 50%.
Assessment of reporting biases
There were too few studies to enable investigation of publication
bias using funnel plots.
Unit of analysis issues
All included trials followed a simple parallel group design, where
children were individually randomized to either isoniazid prophy-
laxis or placebo group and a single measurement for each outcome
(i.e. active TB or death) was collected and analyzed.
Data synthesis
We used a fixed-effect meta-analysis incorporating the Mantel-
Haenszel method for dichotomous outcomes and the inverse-vari-
ance method for time-to-event outcomes to pool results across
studies with no significant heterogeneity (Deeks 2008). Where
meta-analysis was inappropriate, we reported individual study re-
sults separately. We used Review Manager 5 for analysis (Review
Manager 2014).We stratified the analysis by whether the children
were receiving ART or not.
Assessment of overall certainty of evidence
We used GRADE methodology to assess the overall certainty of
evidence (Guyatt 2008). In evaluating the certainty of RCT ev-
idence, we considered the following in whether to downgrade
the certainty of evidence:methodological limitations, unexplained
heterogeneity or inconsistency of study results, indirectness of ev-
idence, imprecision of results, and risk for publication bias. We
rated the certainty across studies as high, moderate, low, or very
low.
We used GRADEpro software to create two ’Summary of find-
ings’ tables for the comparisons ’isoniazid prophylaxis compared
to placebo for HIV-positive children not on ART’ and ’isoniazid
prophylaxis compared to placebo for HIV-positive children on
ART’ (GRADEproGDT2014).We included active TB and death
outcomes in the ’Summary of findings’ tables.
MZ and OA independently assessed the certainty of the evidence.
We resolved disagreements on certainty ratings by discussion and
provided justification for decisions to down- or upgrade the rat-
ings using footnotes in the ‘Summary of findings’ table and made
comments to aid readers’ understanding of the review, where nec-
essary. We used plain language statements to report these findings
in the review.
Subgroup analysis and investigation of heterogeneity
Weconsidered a subgroup analysis based onbackgroundTBpreva-
lence, but all studies were from high TB prevalence settings. We
will consider subgroup analysis by background TB prevalence in
subsequent review updates.
Sensitivity analysis
We could not perform sensitivity analysis due to limited number
of trials included in the review.
R E S U L T S
Description of studies
Results of the search
In the updated search (17 February 2017) we identified an ad-
ditional two RCTs with 714 participants. We found no ongoing
studies in the updated search (Figure 1).
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Figure 1. Study flow diagram.
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Included studies
Design
We included three randomized controlled trials (RCTs) with a
total of 991 participants in the review (Characteristics of included
studies). Two trials were conducted in South Africa (Gray 2014;
Zar 2007), and one was a multicentre trial that was conducted
in South Africa and Botswana; however, enrolment in Botswana
began shortly before the study was terminated (Madhi 2011).
Participants
HIV-positive children in Zar 2007 and Gray 2014 were older
(median age 24.7 to 38 months) than those in Madhi 2011 (me-
dian age 3.2 months). Zar 2007 and Gray 2014 included children
who had a previous history of TB treatment or prophylaxis, 16%
and 12%, respectively, compared to Madhi 2011, that excluded
all children who had a history of TB or known exposure to a mi-
crobiologically confirmed case of TB. Compared to Madhi 2011
and Gray 2014, children in Zar 2007 were severely malnourished
at enrolment: median weight-for-age z-score −0.88 versus -1.56.
Children in Zar 2007 (88% with a Centers for Disease Control
and Prevention (CDC) category B or C) and Gray 2014 (92%
with World Health Organization (WHO) classification Stage 3
or 4) were more likely to be severely immuno-compromised com-
pared to children in Madhi 2011 (8% with a CDC category B or
C).
Participant inclusion and exclusion criteria are described in the
Characteristics of included studies tables.
Interventions
Included studies randomly assigned children to isoniazid prophy-
laxis or placebo group. The dose of isoniazid prophylaxis (10 mg/
kg with a variability of 8 mg/kg to 12 mg/kg) and frequency of
treatment (either daily or three times weekly) were similar in Zar
2007 andGray 2014 compared toMadhi 2011, where children re-
ceived 10 mg/kg to 20 mg/kg of isoniazid daily. Children assigned
to the control groups received placebo with identical appearance
to isoniazid prophylaxis tablets, and administered in a similar way
to isoniazid prophylaxis in the respective studies.
In Zar 2007, ART was initiated in 9% of children at baseline and
in 22% during the trial. In Madhi 2011, ART was initiated at
baseline in approximately 20% of HIV-positive children and in
98.9% within the first year. All children in Gray 2014 were on
ART. The analysis was stratified as such. In addition, only HIV-
positive children in Zar 2007 and Madhi 2011 received 5 mg/kg
of cotrimoxazole.
Primary outcome
Active TBwas similarly defined across all three trials (see the ’Types
of outcome measures’ section).
Excluded studies
Weexcluded six studies on reviewof full articles, seeCharacteristics
of excluded studies tables for details.
Risk of bias in included studies
We have presented the risk of bias for each included trial in the
’Risk of bias’ table in the ’Characteristics of included studies’ tables.
The ’Risk of bias’ summary presents the review authors’ judge-
ments on the risk of bias in each domain, for each trial separately
(Figure 2), while the ’Risk of bias’ graph presents the risk of bias
in each domain as a percentage across all included trials (Figure
3). A summary of our findings on study methodological quality
for each domain follows below.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each ’Risk of bias’ item for each
included study.
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Figure 3. ’Risk of bias’ graph: review authors’ judgements about each ’Risk of bias’ item presented as
percentages across all included studies.
Allocation
Variable block random lists were used by Zar 2007 and Gray 2014
for sequence generation;Madhi 2011 created the random list using
permuted blocks. Treatment groups were centrally allocated in
all three trials (Zar 2007; Madhi 2011; Gray 2014). Methods
of sequence generation were random and adequate for the three
studies (Zar 2007;Madhi 2011; Gray 2014). Treatment allocation
was adequately concealed in all three trials (Zar 2007;Madhi 2011;
Gray 2014).
Blinding
In Zar 2007, participants, personnel, and investigators assessing
the outcome, including an independent outcome assessor, were
blinded to study treatment allocation. Participants, caregivers, in-
vestigators, and endpoint review committeewere unaware of study
group assignment inMadhi 2011. Participants and personnel were
blinded inGray 2014. The radiologist and the clinician (outcomes
assessors) were blinded to the prophylactic regimen to which the
child was allocated (Gray 2014). We assessed the three studies as
having low risk of participant and personnel performance bias and
detection bias (Zar 2007; Madhi 2011; Gray 2014).
Incomplete outcome data
The three studies were at low risk of attrition bias, because the
attrition rate was below 20% in one study (Zar 2007), and all
participants randomized were included in analysis in two trials
(Madhi 2011; Gray 2014).
Selective reporting
We judged risk of reporting bias to be low in all three trials (Zar
2007; Madhi 2011; Gray 2014). All outcomes stated in the study
protocols were reported in the published manuscripts.
Other potential sources of bias
The risk of other bias was unclear in one study; the data safety
monitoring board recommended randomization into the placebo
group to be stopped after 277 of the planned 432 participants
were enrolled (Zar 2007). Two studies were at low risk of other
potential sources of bias (Madhi 2011; Gray 2014).
Effects of interventions
See: Summary of findings for the main comparison Isoniazid
prophylaxis compared to placebo forHIV-positive children not on
antiretroviral therapy (ART); Summary of findings 2 Isoniazid
prophylaxis compared to placebo for HIV-positive children on
antiretroviral therapy (ART)
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Isoniazid versus placebo
HIV-positive children not on antiretroviral therapy (ART)
Active tuberculosis (TB)
One trial from South Africa assessed the effects of isoniazid pro-
phylaxis in HIV-positive children not taking ART. This trial was
stopped early when 263 of 432 (61%) planned participants had
been recruited, due to a result that had reached standard levels of
statistical significance. Isoniazid prophylaxis reduce the number of
children developing active TB by 69% (hazard ratio (HR) 0.31,
95% confidence interval (CI) 0.11 to 0.87; 1 trial, 240 partici-
pants, (review authors own figures), low certainty evidence). The
number of events in this trial was very low. Therefore, we judged
the result to be of low certainty, when downgraded for serious
indirectness and imprecision (Summary of findings for the main
comparison).
Death
In children not taking ART, isoniazid prophylaxis reduces death
by more than 50% (risk ratio (RR) 0.46, 95% CI 0.22 to 0.95;
1 trial, 240 participants, (review authors own figures), low cer-
tainty evidence; Summary of findings for the main comparison).
We downgraded the trial for serious indirectness and imprecision.
Clinical adverse events (grade 3 or higher)
One trial (Zar 2007) reported no clinical adverse events in children
not on ART (Table 1).
Laboratory adverse events (grade 3 or higher)
One trial (182 participants) reported the number of children not
on ART with laboratory adverse events (Zar 2007) (Table 1). Five
and six children had haematological abnormalities (RR 0.83, 95%
CI 0.26 to 2.63) in the isoniazid prophylaxis and placebo groups,
respectively. None of the children in the isoniazid prophylaxis
group, but two in the placebo group had liver enzyme abnormal-
ities.
HIV-positive children on antiretroviral therapy (ART)
Active TB
In HIV-positive children on ART, isoniazid prophylaxis conferred
neither benefit nor harm on active TB (RR 0.76, 95% CI 0.50 to
1.14; 3 trials, 737 participants, very low certainty evidence; Analysis
1.1; Figure 4; Summary of findings 2). The trials and the meta-
analysis were underpowered to detect clinically important effects
and consequently the 95% CI is wide (Table 2). The vast majority
of data were from South Africa, limiting the broad generalization
of the findings to other settings.
Figure 4. Forest plot of comparison: 1 Isoniazid prophylaxis versus placebo, outcome: 1.1 Active TB, HIV-
positive children on ART.
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Death
Isoniazid prophylaxis conferred neither benefit nor harm on death
(RR 1.45, 95% CI 0.78 to 2.72; 3 trials, 737 participants, very low
certainty evidence; Analysis 1.2; Figure 5; Summary of findings 2).
The trials were underpowered to detect clinically important effects
of isoniazid prophylaxis on death (Table 2). We downgraded the
trials for indirectness and serious imprecision.
Figure 5. Forest plot of comparison: 1 Isoniazid prophylaxis versus placebo, outcome: 1.2 Death, HIV-
positive children on ART.
Clinical adverse events (grade 3 or higher)
Two trials (714 participants) reported number of clinical adverse
events (Table 1). Three and two peripheral neuropathy abnormal-
ities occurred in the isoniazid prophylaxis and placebo groups, re-
spectively (Madhi 2011); 15 and 24 other clinical adverse events
respectively, occurred in the isoniazid prophylaxis and placebo
groups (Madhi 2011; Gray 2014).
Laboratory adverse events (grade 3 or higher)
Three trials (795 participants) reported number of laboratory ad-
verse events (Table 1). There were 10 and 9 haematological abnor-
malities in the isoniazid prophylaxis and placebo groups (Madhi
2011); and 15 and 13 liver enzyme abnormalities in the isoniazid
prophylaxis and placebo groups, respectively (Madhi 2011; Gray
2014).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Isoniazid prophylaxis compared to placebo for HIV-positive children on antiretroviral therapy (ART)
Patient or population: HIV-posit ive children on ART
Settings: any sett ing
Intervention: isoniazid prophylaxis daily or three t imes weekly
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Isoniazid prophylaxis
Active TB 13 per 100 9 per 100
(7 to 15)
RR 0.76
(0.50 to 1.14)
737
(3 trials)
⊕©©©
very low1,2,3,4
due to serious indirect-
ness and imprecision
We don’t know if Isoni-
azid prophylaxis reduce
act ive TB
Death 4 per 100 6 per 100
(3 to 11)
RR 1.45
(0.78 to 2.72)
737
(3 trials)
⊕©©©
very low1,2,3,5
due to serious indirect-
ness and imprecision
We don’t know if Isoni-
azid prophylaxis reduce
death
The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95%CI) is based on the assumed risk in the comparison group
and the relative effect of the intervent ion (and its 95% CI).
Abbreviations: CI: conf idence interval; RR: risk rat io.
GRADE Working Group grades of evidence
High certainty: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate certainty: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low certainty: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low certainty: we are very uncertain about the est imate.
1No serious risk of bias: trials were at low risk of select ion bias. Both studies adequately blinded study part icipants and
personnel.16
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D I S C U S S I O N
Summary of main results
In HIV-positive children not taking antiretroviral therapy (ART),
isoniazid prophylaxis may reduce active TB disease (low certainty
evidence), and death (low certainty evidence). In HIV-positive
children without known exposure to a TB source case, and on
ART, isoniazid prophylaxis conferred neither benefit nor harm
for active TB (very low certainty evidence) or death (very low
certainty evidence). HIV treatment may modify the effect of TB
preventive treatment. Clinical adverse events were similar between
the isoniazid prophylaxis and placebo groups, both in children not
on ART and those on ART. Laboratory adverse events were similar
between the isoniazid prophylaxis and placebo groups, both in
children not on ART and those on ART. In a secondary analysis of
Zar 2007 data, Le Roux 2013 showed that 16 (5.4%) out of 297
children developed severe liver injury while receiving isoniazid, but
that only 1.7% of these cases were related to isoniazid prophylaxis.
Overall completeness and applicability of
evidence
Isoniazid preventive therapy is currently recommended for pre-
venting TB infection in HIV-positive children.We included three
trials (n = 991) in this review, which enrolled both young and older
HIV-positive children, living in areas of high TB prevalence.Most
of the data were from South Africa, limiting the generalizability
of the review findings to other settings, given the variation in iso-
niazid resistance globally. The trials were underpowered to detect
clinically important effects of isoniazid prophylaxis on active TB
and death in HIV-positive children taking ART. ART is known to
protect against TB disease, and adequately powered randomized
controlled trials (RCTs) are therefore required to assess the possi-
bility of isoniazid prophylaxis efficacy added to ART. Further data
on isoniazid prophylaxis efficacy at varying levels of immunosup-
pression (HIV disease) are required.
Quality of the evidence
We used the GRADE approach to rate the certainty of the evi-
dence GRADEproGDT 2014. In evaluating the certainty of RCT
evidence, we considered the following in whether to downgrade
the certainty of the evidence: methodological limitations, incon-
sistency in study results, indirectness, imprecision, and publica-
tion bias. We presented the evidence in two ’Summary of findings’
tables for isoniazid prophylaxis efficacy; one for HIV-positive chil-
dren not on ART (Summary of findings for themain comparison),
and the other for HIV-positive children on ART (Summary of
findings 2). The evidence on the effect of isoniazid prophylaxis for
active TB and death in HIV-positive children not on ART was of
low certainty. The effect of isoniazid prophylaxis for active TB and
death in HIV-positive children on ART was inconclusive and the
evidence was of very low certainty. We downgraded the trials for
serious indirectness and imprecision because all were conducted
in one setting and were underpowered with wide confidence in-
tervals.
Potential biases in the review process
We conducted an extensive and comprehensive search of electronic
databases, with no language restrictions, to identify published and
unpublished trials. MZ and TY independently performed study
selection. MZ and OA independently extracted the data and as-
sessed the methodological quality of included studies. Review au-
thors who authored an included study, were not involved in ex-
traction of data and assessment of methodological quality of any
included studies, to maintain independence of the review.
Agreements and disagreements with other
studies or reviews
The results of this review were similar to those from a review of
isoniazid prophylaxis in adults (Akolo 2010). Isoniazid prophy-
laxis had a greater protective effect on TB disease in HIV-positive
children not on ART, reducing the chance of developing active
childhood TB disease by 69%, similar to the 62% reduction in
risk of active disease, found in the adult review (Akolo 2010). Ev-
idence on impact of isoniazid prophylaxis on death in HIV-posi-
tive children not on ART, showed a 54% reduction in death (Zar
2007). In contrast, isoniazid prophylaxis had no significant effect
on TB disease and death in HIV-positive children on ART; these
findings were consistent with the Akolo 2010 review in HIV-pos-
itive adults, reporting no effect on death, in a comparison of any
drug for TB versus placebo. These findings may be consistent with
the protective effect of ART, in reducing the risk of TB disease
and death in HIV-positive children.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Isoniazid prophylaxis may reduce active tuberculosis (TB) disease
and death in HIV-positive children not on antiretroviral ther-
apy (ART). The WHO 2013 guidelines recommend ART for all
HIV-positive children, which has to be started soon after diagno-
sis (WHO 2013). However, many children have delayed access to
ART and coverage is not universal in most sub-Saharan settings,
suggesting that any child awaiting ART in a high TB prevalence
area, should have isoniazid prophylaxis until the child is virally
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suppressed and immune reconstituted. Baseline risk of HIV-pos-
itive children on ART, benefits and harms should be considered
when making treatment decisions.
Implications for research
The risk of TB is substantially higher in HIV-positive children on
ART compared to HIV-negative children from the same commu-
nity. InMadhi 2011, children on ART had a higher rate of TB dis-
ease, 121 cases per 1000 child-years than HIV-negative children,
41 per 1000 child-years. Adequately powered trials assessing the
impact of TBpreventive therapy inHIV-positive children on ART
are required. A target sample size of 848 HIV-positive children
on ART will be required to have an 80% chance of detecting a
43% relative reduction, as significant at the 5% level, in the inter-
vention group assuming a 14% baseline risk in active TB disease
outcome. Trials that assess the long-term effects of TB prophylaxis
are also needed to better assess the length of benefit in different
settings. The three included trials investigated isoniazid prophy-
laxis versus placebo. There are no data on the efficacy of other TB
preventive treatment regimens. Studies in adults included multi-
ple-drug combination preventive treatment (Akolo 2010). How-
ever adverse events leading to discontinuation of treatment were
more common for multiple-drug therapy, as opposed to isoniazid
treatment alone (Akolo 2010).
Although most cases of definite TB in the included studies were
sensitive to isoniazid prophylaxis, long-term data on the impact
of isoniazid prophylaxis on Mycobacterium tuberculosis sensitivity
are needed.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Gray 2014
Methods Trial design: double-blind, randomized placebo-controlled trial
Follow-up: full blood count, liver function tests, urea and electrolyte tests, percentage of
CD4 cells and viral load were measured at baseline and 6-monthly. CXR was performed
at baseline, and additional CXRs were taken if clinically indicated
Adverse events: symptoms of adverse reactions to INH were recorded at each study visit
Participants Number of participants: 167
Median (IQR) age at baseline: 35 months (15 to 65)
Inclusion criteria: age > 8 weeks, on ART for greater than 2 months, weight > 2.5 kg,
adherence to ART of > 90%, prior history of TB treatment or prophylaxis, informed
consent, resident in the area, access to transport
Exclusion criteria: chronic diarrhoea, currently using isoniazid prophylaxis, exposure to
a TB contact, history of prior isoniazid hypersensitivity, severe anaemia (haemoglobin
less than 7 gm/dL), neutropenia (absolute neutrophil count less than 400 cells/µL),
thrombocytopenia (platelet count less than 50 000/µL), non-reversible renal failure
Interventions 1. Isoniazid, 10 mg/kg/dose with a variability of 8 mg/kg to 12 mg/kg, either three
times weekly or daily for a median duration of 34 months.
2. Placebo, had an identical appearance to isoniazid tablet, received either three
times weekly or daily for a median duration of 34 months.
All children were on ART and had adherence of at least 90% at baseline
Outcomes 1. Active TB
2. Death
3. Adverse events
Not included in this review
1. Adherence to TB treatment
2. Hospital admissions
Notes Definitions:
- Definite TB: a microbiological or histological identification ofMycobacterium tubercu-
losis.
- Probable TB: based on a combination of typical clinical symptoms and signs, tuberculin
skin testing, chest radiography, a history of close TB contact, and a documented response
to antimycobacterial therapy
Country: South Africa
Prevalence of isoniazid resistance: 0%
Positive tuberculin test: 16%
Funding: The study was funded by the Medical Research Council, South Africa; the
National Research Foundation, Department of Health, South Africa; and the Discovery
Foundation
Risk of bias
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Gray 2014 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomization list was created using per-
muted blocks, stratified by HIV infection
status and balanced by study site
Allocation concealment (selection bias) Low risk Treatment groups were centrally allocated.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Placebo had an identical appearance to
INHtablets andwas administered in a dou-
ble blind matter”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The chest radiographs were reported by a
radiologist blinded to the prophylactic regi-
men towhich the childwas allocated.Diag-
nosis of TB was independently reviewed by
an experienced clinician blinded to study
randomisation”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis was followed.
All participants randomized were included
in analysis
Selective reporting (reporting bias) Low risk Outcomes stated in the protocol were in-
cluded in the published manuscript
Other bias Low risk None suspected.
Madhi 2011
Methods Trial design: multicentre, phase 2-3, randomized, double-blind, placebo-controlled trial
Follow-up: TB disease-free survival and incidence of TB disease at 96 weeks after ran-
domization
Adverse events: liver enzyme tests, blood counts, clinical neurologic evaluations for pe-
ripheral neuropathy, at scheduled visits every 3 months
Participants Number of participants: 547
Median (IQR) age at baseline: 3 months (3 to 4)
Inclusion criteria: age of 91 to 120days, receivedBacilleCalmette-Guerin (BCG) vaccine,
no history of TB in the infant, known exposure to a microbiological confirmed case of
TB, or active anti-TB treatment in themother at the time of the infant’s birth, no evidence
of failure to thrive, recurrent pneumonia, chronic diarrhoea, or immunosuppressive
conditions other than HIV infection
Exclusion criteria: previous diagnosis of TB infection, previous receipt of isoniazid, con-
tact with a known acid fast bacilli (AFB) sputum smear or culture-positive case of TB
before study entry, current acute or recurrent (3 or more prior episodes) lower respiratory
tract disease, chronic persistent diarrhoea, significant drop in weight or failure to gain
weight appropriately during a 2- to 3-month period, contraindications for use of iso-
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Madhi 2011 (Continued)
niazid or SMX/TMP, require certain medications, known or suspected immune system
diseases other than HIV, current or previous diagnosis of or treatment for cancer, cur-
rent immunosuppressive therapy greater than 1 mg/kg/day of prednisone or equivalent,
anticipated long-term oral or intravenous corticosteroid therapy (greater than 3 weeks),
those receiving nonsteroidal anti-inflammatory agents and inhaled corticosteroids were
not excluded, grade 3 or greater AST/SGOT, ALT/SGPT, ANC, haemoglobin, platelet
count, rash, neuropathy, or myopathy at screening, any grade 4 clinical or laboratory
toxicity within 14 days prior to study entry, other acute or chronic conditions that, in
the opinion of the investigator, may interfere with the study
Interventions 1. Isoniazid prophylaxis, daily, at a dose of 10 mg/kg to 20 mg/kg of body weight for
96 weeks
2. Placebo, daily for 96 weeks
At baseline, 98.7% of the children were on ART. ART mainly included stavudine,
lamivudine, and lopinavir-ritonavir or zidovudine, lamivudine, and lopinavir- ritonavir,
following per country-specific guidelines
Outcomes 1. Active TB
2. Death
3. Adverse events
Not included in this review
1. Compliance with study drug
2. HIV disease progression
Notes Definitions:
- Definite TB: a microbiological or histological identification ofMycobacterium tubercu-
losis.
- Probable TB: based on a combination of typical clinical symptoms and signs, tuberculin
skin testing, chest radiography, a history of close TB contact, and a documented response
to antimycobacterial therapy
All infants were enrolled in the first 6 months of life. The study included HIV-unin-
fected children with outcomes defined differently for this subgroup, however, analysis
of HIV-uninfected children was not included in this review. All HIV-infected children
also received trimethoprim-sulfamethoxazole prophylaxis 5 mg/kg according to WHO
guidelines
TB disease-free survival was defined as the first occurrence of death from any cause or
TB disease, 96 weeks after randomization. HIV disease progression, was defined as the
first occurrence of worsening of the Centers for Diseases Control and Prevention (CDC)
clinical categorization of HIV infection or death
Country: South Africa, Botswana
Prevalence of isoniazid resistance (95% CI): 26% (9 to 51)
Positive tuberculin test: not reported
Funding: The study was supported by the Statistical and Data Analysis Center at the
Harvard School of Public Health, under NIAID cooperative agreements with the Pe-
diatric AIDS Clinical Trials Group (5 U01 AI41110) and the IMPAACT Group (1
U01 AI068616); NIAID and the NICHD International and Domestic Pediatric and
Maternal HIV Clinical Trials Network (NICHD contract number N01-DK-9-001/
HHSN267200-800001C); Secure the Future Fund, a philanthropy program sponsored
by Bristol-Myers Squibb
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Madhi 2011 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization list was created using per-
muted blocks”.
Allocation concealment (selection bias) Low risk Treatment groups were centrally allocated.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants, caregivers and investigators
were blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “End point review committee was unaware
of study-group assignments”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis was followed,
however, its not clear if all enrolled partic-
ipants were included in analysis
Selective reporting (reporting bias) Low risk All important outcomes stated in the study
protocol were reported in the published
manuscript
Other bias Low risk None suspected.
Zar 2007
Methods Trial design: double-blind, placebo-controlled trial.
Follow-up: children underwent a tuberculin skin test and chest radiography if clinically
indicated
Adverse events: alanine transaminase were measured one and three months after ran-
domization and thereafter six-monthly or more frequently if clinically indicated
Participants Number of participants: 277
Median (IQR) age at baseline: 25 months (9 to 52)
Inclusion criteria: age > 8 weeks, weight > 2.5 kg, access to transport, informed consent,
children stable on ART for two to three months
Exclusion criteria: chronic diarrhoea, current use of or need for isoniazid prophylaxis,
previous hypersensitivity to isoniazid or sulphur containing drugs, haemoglobin < 70 g/
L, neutrophil count < 400 cell/uL, platelet count < 50,000 x109/L, non-reversible renal
failure.
Interventions 1. Isoniazid: 10 mg/kg/dose with a variability of 8 mg/kg to 12 mg/kg, either daily
or three times a week on Monday, Wednesday, and Friday for a median duration of 5.7
months.
2. Placebo, identical in appearance to isoniazid tablets, either daily or three times a
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Zar 2007 (Continued)
week on Monday, Wednesday, and Friday for a median duration of 5.7 months.
ARTwas notwidely available. Some children obtained treatment through participation in
pharmaceutical trials or charitable donations. 23 of 263 (9%) were on ART at enrolment
and 58 (22%) started treatment during the trial
Outcomes 1. Active TB
2. Death
3. Adverse events
Not included in this review: none
Notes Definitions:
- Definite TB: a microbiological or histological identification ofMycobacterium tubercu-
losis.
- Probable TB: based on a combination of typical clinical symptoms and signs, tuberculin
skin testing, chest radiography, a history of close TB contact, and a documented response
to antimycobacterial therapy
Cotrimoxazole (5 mg/kg/dose of the trimethoprim component): Given to all children
< 12 months and those older with clinical CDC category B or C disease, in those with
severe immunological impairment (CD4 count of < 15% of total lymphocyte count), or
in those with previous episode of Pneumocystis jirovecii pneumonia. Study was planned to
run for 2 years, however, the placebo arm was terminated early on the recommendation
of the data safety monitoring board on the basis of the results of interim analyses. About
30% of the children received ART during the trial with similar percentages in isoniazid
and placebo groups. Adverse events were graded 1 to 4 according to the toxicity criteria
of the National Institutes of Health’s division of AIDS (DAIDS). Grade 3 and 4 events
were reported
Country: South Africa
Prevalence of isoniazid resistance: 0%
Positive tuberculin test: 9%
Funding: The study was supported by Rockefeller Foundation, USA
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A variable block random listwas used.Gen-
eration of allocation sequence was achieved
by variable blocked randomization lists pre-
pared by the trial statistician and sent to
each trial site pharmacist in a sealed opaque
envelope
Allocation concealment (selection bias) Low risk Central allocation (pharmacists labelled
trial drugs with sequential numbers). The
participants were allocated study numbers
sequentially by the study nurse at enrol-
ment. They were then sequentially allo-
cated to treatment group by the pharmacist
according to the prepared list
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Zar 2007 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo was manufactured to have an iden-
tical appearance to isoniazid, participants
and personnel were blinded to study assign-
ment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Investigators assessing the outcome and
were blinded, the diagnosis of probable TB
was subject to independent review by a
blinded investigator
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rate was very low, < 20%.
Selective reporting (reporting bias) Low risk All outcomes stated in the study protocol
were the same as those in the published
manuscript
Other bias Unclear risk The data safety monitoring board recom-
mended randomization into placebo to be
stopped after 277 of the planned 432 were
enrolled. The placebo armwas ended on 17
May 2004 on the recommendation of the
data safety monitoring board on the basis
of the results of interim analyses
Abbreviations:
ALT/SGPT: Alanine aminotransferase (serum glutamic pyruvic transaminase)
ANC: Absolute neutrophil count
ART: Antiretroviral therapy
AST/SGOT: Aspartate aminotransferase (serum glutamic-oxaloacetic transaminase)
CDC: Centers for Diseases Control and Prevention
CXR: Chest x-rays
INH: Isoniazid
SMX/TMP: Trimethoprim/Sulfamethoxazole
TB: Tuberculosis
WHO: World Health Organization
Characteristics of excluded studies [ordered by study ID]
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Study Reason for exclusion
Frigati 2011 A cohort study.
Hesseling 2012 Secondary analysis of Madhi 2011.
Iro 2013 Commentary.
le Roux 2009 Not addressing review outcomes; secondary analysis of Zar 2007.
Le Roux 2013 Cohort study. Secondary analysis of Zar 2007.
Marais 2013 Commentary.
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D A T A A N D A N A L Y S E S
Comparison 1. Isoniazid prophylaxis versus placebo for HIV-positive children on antiretroviral therapy (ART)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Active TB 3 737 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.50, 1.14]
2 Death 3 737 Risk Ratio (M-H, Fixed, 95% CI) 1.45 [0.78, 2.72]
Analysis 1.1. Comparison 1 Isoniazid prophylaxis versus placebo for HIV-positive children on antiretroviral
therapy (ART), Outcome 1 Active TB.
Review: Isoniazid for preventing tuberculosis in HIV-infected children
Comparison: 1 Isoniazid prophylaxis versus placebo for HIV-positive children on antiretroviral therapy (ART)
Outcome: 1 Active TB
Study or subgroup Isoniazid Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Madhi 2011 (1) 31/273 38/274 81.2 % 0.82 [ 0.53, 1.28 ]
Gray 2014 (2) 4/85 7/82 15.2 % 0.55 [ 0.17, 1.81 ]
Zar 2007 (3) 0/13 1/10 3.6 % 0.26 [ 0.01, 5.82 ]
Total (95% CI) 371 366 100.0 % 0.76 [ 0.50, 1.14 ]
Total events: 35 (Isoniazid), 46 (Placebo)
Heterogeneity: Chi2 = 0.84, df = 2 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.32 (P = 0.19)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours isoniazid Favours placebo
(1) Mahdi 2011: All children on co-trimoxazole, and 98.9% on ART; randomized to 10-20mg/kg INH per day versus placebo.
(2) Gray 2014: Number of children on co-trimoxazole not stated, 100% on ART; randomized to 8-12 mg/kg INH per day or thrice weekly versus placebo.
(3) ZAR 2007: All children on cotrimoxazole, only 9% of those randomized were on ART at baseline; randomized to 8-12 mg/kg INH daily or thrice weekly versus placebo
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Analysis 1.2. Comparison 1 Isoniazid prophylaxis versus placebo for HIV-positive children on antiretroviral
therapy (ART), Outcome 2 Death.
Review: Isoniazid for preventing tuberculosis in HIV-infected children
Comparison: 1 Isoniazid prophylaxis versus placebo for HIV-positive children on antiretroviral therapy (ART)
Outcome: 2 Death
Study or subgroup Isoniazid Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Madhi 2011 (1) 21/273 15/274 96.7 % 1.41 [ 0.74, 2.67 ]
Zar 2007 (2) 0/13 0/10 Not estimable
Gray 2014 (3) 1/85 0/82 3.3 % 2.90 [ 0.12, 70.07 ]
Total (95% CI) 371 366 100.0 % 1.45 [ 0.78, 2.72 ]
Total events: 22 (Isoniazid), 15 (Placebo)
Heterogeneity: Chi2 = 0.19, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours isoniazid Favours placebo
(1) Mahdi 2011: All children on co-trimoxazole, and 98.9% on ART; randomized to 10-20mg/kg INH per day versus placebo.
(2) ZAR 2007: All children on cotrimoxazole, only 9% of those randomized were on ART at baseline; randomized to 8-12 mg/kg INH daily or thrice weekly versus placebo
(3) Gray 2014: Number of children on co-trimoxazole not stated, 100% on ART; randomized to 8-12 mg/kg INH per day or thrice weekly versus placebo.
A D D I T I O N A L T A B L E S
Table 1. Number of children with adverse events and number of adverse events (of grade 3 or higher) in HIV-positive children
on antiretroviral therapy (ART) and not on ART, by study
Number of children with adverse events Number of adverse events
Zar 2007 Madhi 2011 Gray 2014
Children not on ART Children on ART Children on ART Children on ART
Isoni-
azid prophy-
laxis group
N = 91
Placebo
group
N = 91
Isoni-
azid prophy-
laxis group
N = 41
Placebo
group
N = 40
Isoni-
azid prophy-
laxis group
N = 273
Placebo
group
N = 274
Isoni-
azid prophy-
laxis group
N= 85
Placebo
group
N = 82
Clinical adverse events
Peripheral
neuropathy
Not
reported
Not
reported
Not
reported
Not
reported
3 2 Not
reported
Not
reported
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Table 1. Number of children with adverse events and number of adverse events (of grade 3 or higher) in HIV-positive children
on antiretroviral therapy (ART) and not on ART, by study (Continued)
Other clin-
ical adverse
events
Not
reported
Not
reported
Not
reported
Not
reported
14 23 1 1
Laboratory adverse events
Haemato-
logical (neu-
tropenia,
thrombocy-
topenia,
anaemia)
5 6 0 0 10 9 Not
reported
Not
reported
Liver en-
zyme abnor-
malities
0 2 0 0 12 12 3 1
Other labo-
ratory ad-
verse events
Not
reported
Not
reported
0 0 Not
reported
Not
reported
Not
reported
Not
reported
Abbreviations: ART: antiretroviral therapy; N: number of participants.
Table 2. Optimal information size calculations
Outcome Assumed risk Source Clinically important relative reduction Sample size required1,2
Active TB 46/366 (13%) Analysis 1.1 25% 2990
Death 15/366 (4%) Analysis 1.2 50% 2282
1We based all calculations on: 2-sided tests, with a ratio of 1:1, power of 0.8, and confidence level of 0.05.
2We performed all calculations using: sealedenvelope.com/power/binary-superiority
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
#7 Search (#5 AND #6)
#6 Search (infant[mh] OR infant[tiab] OR infants[tiab] OR infancy[tiab] OR toddler*[tiab] OR preterm*[tiab] OR pre-
matur*[tiab] OR postmatur*[tiab] OR baby[tiab] OR babies[tiab] OR neonat*[tiab] OR newborn[tiab] OR preschool*[tiab]
ORpre-school*[tiab]ORchild[mh]ORchild*[tiab]ORkindergar*[tiab]ORpupil*[tiab]OR schoolchild*[tiab]OR teen*[tiab]
OR youth[tiab] OR youths[tiab] OR youngster*[tiab] OR young person*[tiab] OR young people[tiab] OR minors[mh] OR
minors[tiab] OR puberty[mh] OR puberty[tiab] OR pubescen*[tiab] OR prepubescen*[tiab] OR paediatric*[tiab] OR pe-
diatric*[tiab] OR peadiatric*[tiab] OR schools[mh:noexp] OR school*[tiab] OR kid[tiab] OR kids[tiab] OR boy*[tiab] OR
girl*[tiab] OR creche*[tiab] OR highschool*[tiab] OR juvenil*[tiab] OR adolescent[mh] OR adolescen*[tiab] OR under
ag*[tiab] OR underag*[tiab])
#5 Search (#1 AND #2 AND #3 AND #4)
#4 Search (chemoprevention[mh]ORchemoprevention[tiab]ORchemoprophylaxis[tiab]ORprophylaxis[tiab]ORantitubercular
agents[mh] OR antitubercular agents[tiab] OR antitubercular drugs[tiab] OR antituberculosis drugs[tiab] OR tuberculostatic
agents[tiab] OR preventive therapy[tiab])
#3 Search (tuberculosis[mh] OR tuberculosis[tiab] OR tb[tiab] OR tuberculoses[tiab])
#2 Search (randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] OR placebo [tiab] OR drug
therapy [sh] OR randomly [tiab] OR trial [tiab] OR groups [tiab]) NOT (animals [mh] NOT humans [mh])
#1 Search (HIV Infections[MeSH] OR HIV[MeSH] OR hiv[tiab] OR hiv-1*[tiab] OR hiv-2*[tiab] OR hiv1[tiab] OR hiv2[tiab]
OR hiv infect*[tiab] OR human immunodeficiency virus[tiab] OR human immunedeficiency virus[tiab] OR human immuno-
deficiency virus[tiab] OR human immune-deficiency virus[tiab] OR ((human immun*[tiab]) AND (deficiency virus[tiab])
) OR acquired immunodeficiency syndrome[tiab] OR acquired immunedeficiency syndrome[tiab] OR acquired immuno-
deficiency syndrome[tiab] OR acquired immune-deficiency syndrome[tiab] OR ((acquired immun*[tiab]) AND (deficiency
syndrome[tiab])) OR “sexually transmitted diseases, Viral”[MeSH:NoExp])
Appendix 2. Cochrane library search strategy
#10 #6 and #7 and #8 and #9, in Trials
#9 [mh infant] or infant:ti,ab,kw or infants:ti,ab,kw or infancy:ti,ab,kw or toddler*:ti,ab,kw or preterm*:ti,ab,kw or prematur*:
ti,ab,kw or postmatur*:ti,ab,kw or baby:ti,ab,kw or babies:ti,ab,kw or neonat*:ti,ab,kw or newborn:ti,ab,kw or preschool*:
ti,ab,kw or “pre-school*”:ti,ab,kw or [mh child] or child*:ti,ab,kw or kindergar*:ti,ab,kw or pupil*:ti,ab,kw or schoolchild*:
ti,ab,kw or teen*:ti,ab,kw or youth:ti,ab,kw or youths:ti,ab,kw or youngster*:ti,ab,kw or (young next person*):ti,ab,kw or
(young next people):ti,ab,kw or [mh minors] or minors:ti,ab,kw or [mh puberty] or puberty:ti,ab,kw or pubescen*:ti,ab,kw or
prepubescen*:ti,ab,kw or paediatric*:ti,ab,kw or pediatric*:ti,ab,kw or peadiatric*:ti,ab,kw or [mh ˆschools] or school*:ti,ab,
kw or kid:ti,ab,kw or kids:ti,ab,kw or boy*:ti,ab,kw or girl*:ti,ab,kw or creche*:ti,ab,kw or highschool*:ti,ab,kw or juvenil*:
ti,ab,kw or [mh adolescent] or adolescen*:ti,ab,kw or under ag*:ti,ab,kw or underag*:ti,ab,kw (Word variations have been
searched)
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(Continued)
#8 [mh chemoprevention] or chemoprevention:ti,ab,kw or chemoprophylaxis:ti,ab,kw or prophylaxis:ti,ab,kw or [mh “antitu-
bercular agents”] or (antitubercular agents):ti,ab,kw or (antitubercular drugs):ti,ab,kw or (antituberculosis drugs):ti,ab,kw or
(tuberculostatic agents):ti,ab,kw or (preventive therapy):ti,ab,kw (Word variations have been searched)
#7 [mh tuberculosis] or tuberculosis:ti,ab,kw or tuberculoses:ti,ab,kw or tb:ti,ab,kw
#6 #1 or #2 or #3 or #4 or #5
#5 MeSH descriptor: [Sexually Transmitted Diseases, Viral] this term only
#4 MeSH descriptor: [Lymphoma, AIDS-Related] this term only
#3 hiv or hiv-1* or hiv-2* or hiv1 or hiv2 or (hiv near infect*) or (human immunodeficiency virus) or (human immunedeficiency
virus) or (human immune-deficiency virus) or (human immuno-deficiency virus) or (human immune deficiency virus) or
(human immuno deficiency virus) or (acquired immunodeficiency syndrome) or (acquired immunedeficiency syndrome)
or (acquired immuno-deficiency syndrome) or (acquired immune-deficiency syndrome) or (acquired immun* deficiency
syndrome)
#2 MeSH descriptor: [HIV] explode all trees
#1 MeSH descriptor: [HIV Infections] explode all trees
Appendix 3. EMBASE search strategy
#12 #10 AND #11
#11 ’infant’/exp OR infant:ab,ti OR infants:ab,ti OR infancy:ab,ti OR toddler*:ab,ti OR preterm*:ab,ti OR prematur*:ab,ti OR
postmatur*:ab,ti OR baby:ab,ti OR babies:ab,ti OR neonat*:ab,ti OR newborn:ab,ti OR preschool*:ab,ti OR pre+school*:ab,
ti OR ’child’/exp OR child*:ab,ti OR kindergar*:ab,ti OR pupil*:ab,ti OR schoolchild*:ab,ti OR teen*:ab,ti OR youth:ab,ti
OR youths:ab,ti OR youngster*:ab,ti OR ’young person’:ab,ti OR ’young persons’:ab,ti OR ’young people’:ab,ti OR ’minors’/
exp OR minors:ab,ti OR ’puberty’/exp OR puberty:ab,ti OR pubescen*:ab,ti OR prepubescen*:ab,ti OR paediatric*:ab,ti
OR pediatric*:ab,ti OR peadiatric*:ab,ti OR ’schools’/exp OR school*:ab,ti OR kid:ab,ti OR kids:ab,ti OR boy*:ab,ti OR
girl*:ab,ti OR creche*:ab,ti OR highschool*:ab,ti OR ’juvenile’/exp OR juvenil*:ab,ti OR ’adolescent’/exp OR adolescen*:
ab,ti OR (under NEXT/1 ag*):ab,ti OR underag*:ab,ti
#10 #1 AND #7 AND #8 AND #9
#9 ’chemoprevention’/de OR chemoprevention:ab,ti OR ’chemoprophylaxis’/de OR chemoprophylaxis:ab,ti OR prophylaxis:
ab,ti OR (antitubercular NEXT/1 (agent* OR drug*)):ab,ti OR (’anti tubercular’ NEXT/1 (agent* OR drug*)):ab,ti OR
(antituberculosis NEXT/1 (agent* OR drug*)):ab,ti OR ’tuberculostatic agent’/de OR (tuberculostatic NEXT/1 agent*):ab,
ti OR ’preventive therapy’:ab,ti
#8 ’tuberculosis’/exp OR tuberculosis:ab,ti OR tuberculoses:ab,ti OR tb:ab,ti
#7 #2 NOT #6
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(Continued)
#6 #3 NOT #5
#5 #3 AND #4
#4 ’human’/de OR ’normal human’/de OR ’human cell’/de
#3 ’animal’/de OR ’animal experiment’/de OR ’invertebrate’/de OR ’animal tissue’/de OR ’animal cell’/de OR ’nonhuman’/de
#2 ’randomized controlled trial’/deOR ’randomized controlled trial’OR random*:ab,tiOR trial:tiORallocat*:ab,tiOR factorial*:
ab,ti OR placebo*:ab,ti OR assign*:ab,ti OR volunteer*:ab,ti OR ’crossover procedure’/de OR ’crossover procedure’ OR
’double-blind procedure’/de OR ’double-blind procedure’ OR ’single-blind procedure’/de OR ’single-blind procedure’ OR
(doubl*NEAR/3 blind*):ab,tiOR (singl*:ab,ti ANDblind*:ab,ti)OR crossover*:ab,tiOR cross+over*:ab,tiOR (crossNEXT/
1 over*):ab,ti
#1 ’human immunodeficiency virus infection’/exp OR ’human immunodeficiency virus’/exp OR ’human immunodefi-
ciency virus’:ab,ti OR ’human immuno+deficiency virus’:ab,ti OR ’human immunedeficiency virus’:ab,ti OR ’human im-
mune+deficiency virus’:ab,ti OR hiv:ab,ti OR ’hiv-1’:ab,ti OR ’hiv-2’:ab,ti OR ’acquired immunodeficiency syndrome’:ab,
ti OR ’acquired immuno+deficiency syndrome’:ab,ti OR ’acquired immunedeficiency syndrome’:ab,ti OR ’acquired im-
mune+deficiency syndrome’:ab,ti
WH A T ’ S N E W
Last assessed as up-to-date: 17 February 2017.
Date Event Description
18 August 2017 New citation required and conclusions have changed Search updated and new studies added.
17 February 2017 New search has been performed Search updated and new studies added. A new author
joined the team
H I S T O R Y
Protocol first published: Issue 1, 2007
Review first published: Issue 1, 2009
35Isoniazid for preventing tuberculosis in HIV-infected children (Review)
Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Date Event Description
24 June 2009 Amended Added author whose name had inadvertently been omit-
ted.
21 March 2006 New citation required and conclusions have changed Substantive amendment
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
This is an update of the 2009 version Gray 2009b of this review. Gray 2009b included one completed and two ongoing RCTs. The
latter two RCTs are complete and now included in the update. An updated search identified no other studies. The methods now include
the latest Cochrane risk of bias assessment tool, GRADE and Summary of findings tables. Findings are stratified into HIV positive
children on ART and not on ART. Moleen Zunza joined the author team.
I N D E X T E R M S
Medical Subject Headings (MeSH)
AIDS-Related Opportunistic Infections [mortality; ∗prevention & control]; Anti-HIV Agents [therapeutic use]; Antitubercular Agents
[adverse effects; ∗therapeutic use]; HIV Infections [drug therapy; ∗mortality]; Incidence; Isoniazid [adverse effects; ∗therapeutic use];
Randomized Controlled Trials as Topic; Trimethoprim, Sulfamethoxazole Drug Combination [adverse effects; therapeutic use]; Tu-
berculosis, Multidrug-Resistant [epidemiology]; Tuberculosis, Pulmonary [drug therapy; ∗mortality; ∗prevention & control]
MeSH check words
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